CD36 in Alzheimer’s Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
CD36 is a membrane protein with wide distribution in the human body, is enriched in the monocyte-macrophage system and endothelial cells, and is involved in the cellular uptake of long chain fatty acids (LCFA) and oxidized low-density lipoproteins. It is also a scavenger receptor, binding hydrophobic amyloid fibrils found in the Alzheimer's disease (AD) brain. In neurobiology research, it has been mostly studied in relationship with chronic ischemia and stroke, but it was also related to amyloid clearance by microglial phagocytosis. In AD animal models, amyloid binding to CD36 has been consistently correlated with a pro-inflammatory response. Therapeutic approaches have two main focuses: CD36 blockade with monoclonal antibodies or small molecules, which is beneficial in terms of the inflammatory milieu, and upregulation of CD36 for increased amyloid clearance. The balance of the two approaches, centered on microglia, is poorly understood. Furthermore, CD36 evaluation in AD clinical studies is still at a very early stage and there is a gap in the knowledge regarding the impact of LCFA on AD progression and CD36 expression and genetic phenotype. This review summarizes the role played by CD36 in the pathogenic amyloid cascade and explore the translatability of preclinical data towards clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 3×
“…reported in vitro, in microglia (Bamberger et al., 2003; Luster et al., 2003; Tsukahara, 2020) and at amyloid sites in mouse and human brains (Moore et al., 2002; El Khoury et al., 2003; Hickman et al., 2008; Park et al., 2017) (for reviews see (Doens and Fernández, 2014; Nichols et al., 2019)).”
Sheedy, F. J., Grebe, A., Rayner, K. J., Kalantari, P., Ramkhelawon, B., Carpenter, S. B., Becker, C. E., Ediriweera, H. N., Mullick, A. E., Golenbock, D. T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2639 · Cited by 935
A Null Mutation in Murine CD36 Reveals an Important Role in Fatty Acid and Lipoprotein Metabolism
Febbraio, M., Abumrad, N. A., Hajjar, D. P., Sharma, K., Cheng, W., Pearce, S. F. A., & Silverstein, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19055 · Cited by 769
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“Another RCT that recruited patients with mild to moderate AD reported no effect in relation to reducing cognitive decline following DHA treatment (Quinn et al., 2010).”
BackgroundFreund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Mechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527 · cited 2×
“CD36-related Ab clearance by phagocytosis is another focus of microglia (Yamanaka et al., 2012; Ries and Sastre, 2016) and astrocyte (Jones et al.”
Dietary intake of fatty acids and fish in relation to cognitive performance at middle age
Kalmijn, S., van Boxtel, M. P. J., Ocké, M., Verschuren, W. M. M., Kromhout, D., & Launer, L. J. (2004) · Neurology · doi:10.1212/01.wnl.0000103860.75218.a5 · Cited by 524
CD36, a scavenger receptor implicated in atherosclerosis
Park, Y. M. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.38 · Cited by 517
A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501
CD36 Mediates the Innate Host Response to β-Amyloid
El Khoury, J. B., Moore, K. J., Means, T. K., Leung, J., Terada, K., Toft, M., Freeman, M. W., & Luster, A. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021546 · Cited by 483
Cited by
Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity
Victor, M. B., Leary, N., Luna, X., Meharena, H. S., Scannail, A. N., Bozzelli, P. L., Samaan, G., Murdock, M. H., von Maydell, D., Effenberger, A. H., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.005 · Cited by 316
Lipid Accumulation Induced by APOE4 Impairs Microglial Surveillance of Neuronal-Network Activity
Victor, M. B., Leary, N., Luna, X., Meharena, H. S., Bozzelli, P. L., Samaan, G., Murdock, M. H., von Maydell, D., Effenberger, A. H., Cerit, O., et al. (2022) · doi:10.1101/2022.03.21.484146 · Cited by 311
“, 2021), and CD36 has been shown to be downregulated in AD-associated proinflammatory microglia (Dobri et al., 2021).”
BackgroundUekawa, K., Hattori, Y., Ahn, S. J., Seo, J., Casey, N., Anfray, A., Zhou, P., Luo, W., Anrather, J., Park, L., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00660-1 · Cited by 80
“The Aβ-binding scavenger receptor CD36 has been linked to AD [27, 28] and is upregulated in CAA [29].”
Ahmad, Y., Seo, D. S., & Jang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137076 · Cited by 49
“For the synthesis of pro-inflammatory cytokines, CD36 induces the heterodimeric binding of toll-like receptors (TLRs), and the subsequent activation of the Nf-kB transcription factor [143] .”
BackgroundChen, Y., Sun, Y., Luo, Z., Chen, X., Wang, Y., Qi, B., Lin, J., Lin, W.-W., Sun, C., Zhou, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.881488 · Cited by 40
Metadata
- Authors
- Dobri, A.-M., Dudău, M., Enciu, A.-M., & Hinescu, M. E.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 453
- Pages
- 301-311
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W3103621911
- Cited by
- 82
- References
- 31
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD36 in Alzheimer’s Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting. https://app.cochat.ai/papers/10.1016/j.neuroscience.2020.11.003
- The paper
- Dobri, A.-M., Dudău, M., Enciu, A.-M., & Hinescu, M. E. (2021). CD36 in Alzheimer’s Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting. Neuroscience. https://doi.org/10.1016/j.neuroscience.2020.11.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.